Recently, Hussain et al.performed a meta-analysis of the risk of overall bleeding and recurrent VTE in cancer-associated thrombosis treated with factor Xa inhibitors compared with patients treated with LMWHs [35]. The gene discussed is F10; the disease is deep vein thrombosis.